

# Johanna C Kluin-Nelemans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8434542/publications.pdf>

Version: 2024-02-01

182  
papers

13,262  
citations

26610

56  
h-index

24232

110  
g-index

183  
all docs

183  
docs citations

183  
times ranked

10783  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <i>Blood</i> , 2008, 111, 558-565.	0.6	819
2	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. <i>Journal of the National Cancer Institute</i> , 1998, 90, 850-859.	3.0	728
3	Double-hit B-cell lymphomas. <i>Blood</i> , 2011, 117, 2319-2331.	0.6	603
4	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. <i>Blood</i> , 2005, 105, 2677-2684.	0.6	524
5	Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. <i>Blood</i> , 2001, 97, 2549-2554.	0.6	448
6	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1916-1927.	13.9	412
7	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	13.9	383
8	Chronic myeloid leukemia and interferon- $\gamma$ : a study of complete cytogenetic responders. <i>Blood</i> , 2001, 98, 3074-3081.	0.6	309
9	High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <i>Journal of Clinical Oncology</i> , 2003, 21, 4483-4488.	0.8	308
10	Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2003, 348, 2396-2406.	13.9	301
11	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	1.5	289
12	Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1995, 332, 1045-1051.	13.9	278
13	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016, 34, 1386-1394.	0.8	276
14	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , 1999, 94, 1201-1208.	0.6	260
15	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , 2010, 115, 3215-3223.	0.6	243
16	Cladribine therapy for systemic mastocytosis. <i>Blood</i> , 2003, 102, 4270-4276.	0.6	223
17	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 3128-3135.	0.8	216
18	Response to Interferon Alfa-2b in a Patient with Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 1992, 326, 619-623.	13.9	212

#	ARTICLE	IF	CITATIONS
19	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
20	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. <i>British Journal of Haematology</i> , 2001, 112, 950-958.	1.2	200
21	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
22	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. <i>Laboratory Investigation</i> , 2001, 81, 419-426.	1.7	158
23	Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 2912-2919.	0.6	153
24	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	2.0	150
25	Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4135-4142.	0.8	144
26	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	0.8	137
27	Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. <i>British Journal of Haematology</i> , 1988, 70, 55-62.	1.2	134
28	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
29	The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. <i>Blood</i> , 2004, 104, 143-148.	0.6	126
30	Unique Polycomb Gene Expression Pattern in Hodgkin's Lymphoma and Hodgkin's Lymphoma-Derived Cell Lines. <i>American Journal of Pathology</i> , 2004, 164, 873-881.	1.9	123
31	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. <i>Lancet Haematology</i> , 2015, 2, e492-e502.	2.2	123
32	High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. <i>Thrombosis and Haemostasis</i> , 2009, 101, 93-99.	1.8	116
33	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
34	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
35	Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 291-299.	0.8	99
36	Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 2825-2832.	0.8	96

#	ARTICLE	IF	CITATIONS
37	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1160-1170.	5.1	96
38	Early onset post-transplant lymphoproliferative disease is associated with allograft localization. <i>Clinical Transplantation</i> , 2005, 19, 327-334.	0.8	90
39	In Normal Controls, Both Age and Gender Affect Coagulability as Measured by Thrombelastography. <i>Anesthesia and Analgesia</i> , 2010, 110, 987-994.	1.1	86
40	Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis. <i>Journal of Immunology</i> , 2007, 178, 2287-2295.	0.4	85
41	Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 125-130.	1.5	81
42	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	80
43	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. <i>Cancer Treatment Reviews</i> , 2007, 33, 338-346.	3.4	80
44	Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. <i>Haematologica</i> , 2009, 94, 1691-1697.	1.7	80
45	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. <i>Blood</i> , 2005, 105, 2916-2923.	0.6	79
46	Fertility preservation after chemotherapy for Hodgkin lymphoma. <i>Hematological Oncology</i> , 2010, 28, 168-179.	0.8	79
47	Prevalence of indolent systemic mastocytosis in a Dutch region. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1429-1431.e1.	1.5	78
48	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
49	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
50	The Pathogenesis of Venous Thromboembolism: Evidence for Multiple Interrelated Causes. <i>Annals of Internal Medicine</i> , 2006, 145, 807.	2.0	68
51	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 52-56.	1.2	68
52	Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. <i>British Journal of Haematology</i> , 2014, 165, 489-496.	1.2	65
53	Identification of RUNX1/AML1 as a classical tumor suppressor gene. <i>Oncogene</i> , 2003, 22, 538-547.	2.6	64
54	The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. <i>Human Immunology</i> , 2000, 61, 565-574.	1.2	63

#	ARTICLE	IF	CITATIONS
55	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. <i>British Journal of Haematology</i> , 2009, 144, 524-530.	1.2	61
56	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	1.7	60
57	Haemostatic variables during normal menstrual cycle. <i>Thrombosis and Haemostasis</i> , 2012, 107, 22-29.	1.8	57
58	IgD class switching: Identification of a novel recombination site in neoplastic and normal B cells. <i>European Journal of Immunology</i> , 1995, 25, 3504-3508.	1.6	51
59	Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer Trials. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 122-130.	1.4	50
60	The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. <i>Thrombosis Research</i> , 2012, 130, 334-338.	0.8	48
61	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	2.7	47
62	EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. <i>Blood</i> , 2008, 112, 1039-1041.	0.6	45
63	HLA Antigens and Post Renal Transplant Lymphoproliferative Disease: HLA-B Matching Is Critical. <i>Transplantation</i> , 2005, 80, 595-599.	0.5	43
64	The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 202.e1-202.e7.	0.7	43
65	Management around invasive procedures in mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 304-309.	0.5	43
66	Discordant Morphologic Characteristics of B-Cell Lymphomas in Bone Marrow and Lymph Node Biopsies. <i>American Journal of Clinical Pathology</i> , 1990, 94, 59-66.	0.4	42
67	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. <i>Leukemia and Lymphoma</i> , 2014, 55, 526-532.	0.6	42
68	Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1006-1008.e7.	1.5	42
69	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 356-366.e4.	1.5	42
70	Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. <i>British Journal of Haematology</i> , 2005, 128, 703-710.	1.2	40
71	SUCCESSFUL OUTCOME WITH A QUINTUPLE APPROACH OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. <i>Transplantation</i> , 2001, 71, 47-52.	0.5	39
72	Somatic pairing of centromeres and short arms of chromosome 15 in the hematopoietic and lymphoid system. <i>Human Genetics</i> , 1993, 92, 577-582.	1.8	38

#	ARTICLE	IF	CITATIONS
73	Effects of red blood cells on hemostasis. <i>Transfusion</i> , 2010, 50, 1536-1544.	0.8	38
74	Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. <i>Cancer</i> , 2000, 89, 2667-2676.	2.0	37
75	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2013, 54, 699-707.	0.6	37
76	Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. <i>British Journal of Haematology</i> , 2001, 115, 298-308.	1.2	36
77	Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. <i>JAMA Internal Medicine</i> , 2016, 176, 1176.	2.6	36
78	Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. <i>Blood</i> , 2004, 103, 4408-4415.	0.6	34
79	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	3.3	34
80	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.0	33
81	On the use of Cox regression in the presence of an irregularly observed time-dependent covariate. <i>Statistics in Medicine</i> , 2001, 20, 3817-3829.	0.8	32
82	Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3854-3863.	0.8	32
83	Lipid levels do not influence the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 108, 923-929.	1.8	32
84	Granulocytic Sarcoma (chloroma): Presentation of an Unusual Case. <i>American Journal of Clinical Pathology</i> , 1991, 95, 567-571.	0.4	30
85	Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival. , 1997, 79, 390-397.		30
86	Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. <i>Annals of Hematology</i> , 2005, 84, 311-316.	0.8	29
87	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 2226-2236.	0.6	29
88	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	3.3	29
89	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	3.3	29
90	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3121-3127.e1.	2.0	28

#	ARTICLE	IF	CITATIONS
91	No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. <i>Leukemia Research</i> , 1984, 8, 723-728.	0.4	27
92	Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 389-397.	0.5	27
93	Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. <i>Critical Care Medicine</i> , 2019, 47, e120-e128.	0.4	27
94	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	2.2	27
95	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	4.6	26
96	Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. <i>Blood</i> , 2008, 111, 2581-2588.	0.6	25
97	Validation of the <scp>MCL</scp>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	1.2	25
98	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , 1998, 91, 4224-4231.	0.6	24
99	Treatment of Elderly Patients With Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 208-213.	1.8	24
100	Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. <i>British Journal of Haematology</i> , 1989, 72, 439-444.	1.2	23
101	The European Competence Network on Mastocytosis. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 647-651.	1.0	23
102	Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a <i>Haemophilus influenzae</i>-driven immune disorder?. <i>Journal of Pathology</i> , 2015, 236, 302-314.	2.1	23
103	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	1.5	23
104	Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1168-1177.	0.4	22
105	Haematopoietic and immunologic abnormalities in severe aplastic anaemia patients treated with anti-thymocyte globulin. <i>British Journal of Haematology</i> , 1989, 71, 421-430.	1.2	22
106	Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. <i>Journal of Clinical Oncology</i> , 2005, 23, 3793-3801.	0.8	21
107	CD30 in Systemic Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 341-355.	0.7	21
108	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	21

#	ARTICLE	IF	CITATIONS
109	Active cytomegalovirus infection in patients with acute venous thrombosis: A case-control study. <i>American Journal of Hematology</i> , 2011, 86, 510-512.	2.0	20
110	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	2.0	20
111	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic nonâ€mast cell lineage disease (SM-AHNMD). <i>Blood</i> , 2010, 116, 850-851.	0.6	19
112	Pain and Anxiety During Bone Marrow Biopsy. <i>Pain Management Nursing</i> , 2013, 14, 310-317.	0.4	19
113	<scp>MYC</scp> expression and translocation analyses in lowâ€grade and transformed follicular lymphoma. <i>Histopathology</i> , 2017, 71, 960-971.	1.6	19
114	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	0.6	19
115	Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. <i>Haematologica</i> , 2008, 93, 120-123.	1.7	18
116	Low cut-off values increase diagnostic performance of protein S assays. <i>Thrombosis and Haemostasis</i> , 2010, 104, 618-625.	1.8	18
117	Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2074-2079.	0.6	18
118	Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. <i>Scandinavian Journal of Haematology</i> , 1986, 36, 71-78.	0.0	17
119	Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. <i>PLoS ONE</i> , 2016, 11, e0149162.	1.1	17
120	Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a populationâ€based cohort study. <i>British Journal of Haematology</i> , 2012, 156, 667-671.	1.2	16
121	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , 1999, 93, 251-259.	0.6	15
122	Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms. <i>Psycho-Oncology</i> , 2019, 28, 830-838.	1.0	15
123	Interim thymus and activation regulated chemokine versus interim 18 Fâ€fluorodeoxyglucose positronâ€emission tomography in classical Hodgkin lymphoma response evaluation. <i>British Journal of Haematology</i> , 2020, 190, 40-44.	1.2	15
124	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014, 124, 636-636.	0.6	15
125	Characterisation of hairy cell leukaemia by tiling resolution arrayâ€based comparative Genome hybridisation: a series of 13 cases and review of the literature. <i>European Journal of Haematology</i> , 2010, 84, 17-25.	1.1	14
126	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 242-246.	0.6	14



#	ARTICLE	IF	CITATIONS
127	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.3	14
128	Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non-Hodgkin's lymphomas, according to data in the population-based registry of the comprehensive cancer centre west. <i>Cancer</i> , 1998, 83, 1612-1619.	2.0	13
129	Lenalidomide therapy in systemic mastocytosis. <i>Leukemia Research</i> , 2009, 33, e19-e22.	0.4	13
130	Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. <i>Haematologica</i> , 2009, 94, 1546-1554.	1.7	13
131	Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 792-798.	1.5	13
132	Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units. <i>British Journal of Haematology</i> , 2018, 181, 68-76.	1.2	13
133	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 115.	1.0	13
134	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	2.0	13
135	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7500-7500.	0.8	13
136	Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3256-3260.	0.4	12
137	Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. <i>British Journal of Haematology</i> , 2012, 159, 216-222.	1.2	11
138	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , 2013, 8, 1229.	1.3	11
139	Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. <i>Thrombosis and Haemostasis</i> , 2015, 113, 881-890.	1.8	11
140	Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 388-394.	0.9	11
141	Bortezomib maintenance after Râ€CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , 2020, 190, 385-393.	1.2	11
142	Hairy Cell Leukemia and Its T Cell Interactions. <i>Leukemia and Lymphoma</i> , 1991, 4, 159-166.	0.6	10
143	Treatment and Survival of Patients with Thyroid Lymphoma: A Population-Based Study with Clinical and Pathologic Reviews. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 240-247.	1.4	10
144	Routine evaluation and treatment of unexplained menorrhagia: do we consider haemostatic disorders?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 152, 191-194.	0.5	10

#	ARTICLE	IF	CITATIONS
145	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: Results from a retrospective family cohort study. <i>Thrombosis Research</i> , 2010, 126, e249-e254.	0.8	10
146	The impact of <scp>SAMHD1</scp> expression and mutation status in mantle cell lymphoma: An analysis of the <scp>MCL</scp> Younger and Elderly trial. <i>International Journal of Cancer</i> , 2021, 148, 150-160.	2.3	10
147	T-cell prolymphocytic leukemia with an unusual phenotype CD4+ CD8+. <i>Cancer</i> , 1987, 60, 794-803.	2.0	9
148	An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP70 expression in B-cell chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 40-44.	0.7	9
149	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 416-421.	0.8	9
150	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. <i>Blood</i> , 2021, 137, 3251-3258.	0.6	9
151	Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes. <i>PLoS ONE</i> , 2014, 9, e86556.	1.1	8
152	No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. <i>Cancer Epidemiology</i> , 2017, 48, 110-116.	0.8	8
153	What is the optimal initial management of the older MCL patient?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 99-104.	0.7	8
154	High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabine. <i>Blood</i> , 2004, 104, 19-19.	0.6	8
155	NO DIFFERENCE BETWEEN CYTOCHEMICAL AND IMMUNOLOGICAL DETECTION OF MYELOPEROXIDASE IN AML. <i>British Journal of Haematology</i> , 1990, 75, 630-630.	1.2	7
156	Clinical course and pathologic features of conjunctival non-Hodgkin's lymphoma. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 1990, 228, 246-251.	1.0	7
157	Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. <i>Thrombosis Research</i> , 2011, 128, 501-502.	0.8	7
158	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 487-498.	1.4	7
159	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013, 122, 106-106.	0.6	6
160	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , 1999, 94, 1201-1208.	0.6	6
161	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Cancers</i> , 2022, 14, 188.	1.7	6
162	Comparison between clonogenic and cytotoxic assays for measuring lak cell activity. <i>International Journal of Cell Cloning</i> , 1989, 7, 232-241.	1.6	5

#	ARTICLE	IF	CITATIONS
163	Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network. <i>Blood</i> , 2014, 124, 2977-2977.	0.6	4
164	Mismatched transplants for refractory lymphoma?. <i>Lancet, The</i> , 1999, 353, 1725-1726.	6.3	3
165	Splenectomy and second malignancies in patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 230-231.	0.6	3
166	Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study. <i>British Journal of Haematology</i> , 2016, 172, 636-638.	1.2	3
167	Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2677-2677.	0.6	3
168	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , 1998, 91, 4224-4231.	0.6	3
169	Characterization of a New Human B Cell Line (Bonna-12) with Trisomy 9 and Trisomy 12 Chromosomal Abnormality. <i>Leukemia and Lymphoma</i> , 1991, 5, 415-422.	0.6	2
170	The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3. <i>Journal of Immunology</i> , 2004, 173, 6009-6016.	0.4	2
171	A “pre-induction course”™ with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2007, 138, 275-277.	1.2	2
172	PROS1 Heerlen polymorphism is associated with increased free plasma tissue factor pathway inhibitor levels. <i>Thrombosis and Haemostasis</i> , 2012, 107, 594-596.	1.8	2
173	Junior Scientific Masterclass: Additional Science Training for Medical Students. <i>Medical Science Educator</i> , 2011, 21, 86-90.	0.7	1
174	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , 1999, 93, 251-259.	0.6	1
175	Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma. <i>Croatian Medical Journal</i> , 2002, 43, 561-4.	0.2	1
176	Reply to Z. Blumenfeld. <i>Hematological Oncology</i> , 2011, 29, 53-53.	0.8	0
177	Late relapses in diffuse large B-cell lymphoma: where to move next?. <i>Leukemia and Lymphoma</i> , 2020, 61, 1005-1006.	0.6	0
178	Hereditary Protein S Type III Deficiency Is Not a Risk Factor for Venous and Arterial Thrombosis, in Contrast to Protein S Deficiency Type I. Results from a Family Cohort Study To Assess the Clinical Impact of a Laboratory Based Classification.. <i>Blood</i> , 2004, 104, 1056-1056.	0.6	0
179	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.. <i>Blood</i> , 2005, 106, 5389-5389.	0.6	0
180	Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 2313-2313.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2012, 120, 3656-3656.	0.6	0
182	Therapy for stage I aggressive non-Hodgkin's lymphoma. <i>Croatian Medical Journal</i> , 2002, 43, 546-9.	0.2	0